Board of Directors

Laura Bushnell, JD
Laura Bushnell, JD is a member of Vincerx’s board of directors. Ms Bushnell has served as a partner of King & Spalding LLP, a global corporate law firm, since September 2009. Ms Bushnell has served as a member of the board of trustees of the University of California, Santa Cruz, Foundation since February 2015, and as chair of the Dean’s Council of the Baskin School of Engineering at the University of California, Santa Cruz, since July 2019. Since September 2010, Ms Bushnell has served as a member of the board of directors of the Legal Aid Society of San Mateo County. Ms Bushnell received an AB in psychology from Stanford University and a JD from the Georgetown University Law Center.
Brian Druker, MD
Brian Druker, MD is a member of Vincerx’s board of directors. Dr Druker has served in various capacities at the Oregon Health and Science University, as a physician since July 1993, professor since July 2000, and associate dean of Oncology since July 2010. Since July 2007, Dr Druker served as director of the Oregon Health and Science University Knight Cancer Institute. Dr Druker has served as a member of the scientific advisory board of Aptose Biosciences Inc., a biotechnology company, since 2013. Since May 2018, Dr Druker has served as a member of the board of directors of Amgen Inc., a multinational biopharmaceutical company. Dr Druker served as a member of the scientific advisory board of Grail, Inc., a biotechnology company, from May 2016 to September 2019. Dr Druker has been recognized with numerous awards, including the Warren Alpert Prize from Harvard Medical School, the Lasker-DeBakey Award for Clinical Medical Research, the Japan Prize in Healthcare and Medical Technology, and most recently, the 2018 Tang Prize in Biopharmaceutical Science. Dr Druker has been elected to the National Academy of Medicine, the National Academy of Sciences and the American Academy of Arts and Sciences. Dr Druker received a BA in chemistry from the University of California, San Diego, and an MD from the University of San Diego Medicine, San Diego.
Ahmed Hamdy, MD
Ahmed Hamdy, MD is the Chief Executive Officer and Chairman of the board of directors of Vincerx. Dr Hamdy has served as Vincerx’s Chief Executive Officer and as a member Vincerx’s board of directors since March 2019. Before that, Dr Hamdy co-founded Acerta Pharma, a pharmaceutical development company and member of the AstraZeneca plc, and served as its head of early clinical development from January 2015 to June 2019, as chief executive officer from February 2013 to January 2015, as chief medical officer from February 2013 to January 2015 and as a member of the board from February 2013 to February 2016. Before that, Dr Hamdy served as chief medical officer of Pharmacyclics LLC, a biopharmaceutical company, from March 2008 to June 2011. Dr Hamdy has served as a clinical advisor and member of the board of directors of Andes Biotechnologies, a nucleic acid-based drug discovery and development company, since September 2016, as a member of the Dean’s Council of the Jack Baskin School of Engineering at the University of California, Santa Cruz, since April 2019, and as a member of the Palo Alto Medical Foundation President’s Council since March 2016. Dr Hamdy received a MBBCH from the KasrAlainy School of Medicine at the University of Cairo, Egypt.
Chairman of the Board
Raquel Izumi, PhD
Raquel Izumi, PhD is the Chief Operations Officer and President of Vincerx and a member of the Vincerx board of directors. Dr Izumi has served as Vincerx’s Chief Operations Officer and as a member Vincerx’s board of directors since March 2019. Before that, Dr Izumi co-founded Acerta Pharma and served as its executive vice president of clinical development from February 2013 to May 2020. Dr Izumi also co-founded Aspire Therapeutics LLC and served as its chief scientific officer from June 2011 to February 2013. Before founding Aspire Therapeutics, Dr Izumi served as senior director of clinical development at Pharmacyclics LLC, a biopharmaceutical company, from February 2010 to May 2011, where she worked on designing and implementing seven clinical studies across various hematologic malignancies (including three studies that garnered breakthrough therapy designation) for the first BTK inhibitor (IMBRUVICA®) to enter clinical trials. Dr Izumi began her research career at Amgen, where she held positions of increasing responsibility and participated in a successful BLA filing and approval for ARANESP®. Dr Izumi was a Howard Hughes Predoctoral Fellow at the University of California, Los Angeles where she obtained a PhD in microbiology and immunology. She received honors and distinction for her BA in biological sciences from the University of California, Santa Barbara.
John Lee, MD
John Lee, MD is a member of Vincerx’s board of directors. Dr Lee has served as chief medical officer of cancer research of Avera Health, a regional healthcare system, since May 2020 and as chief medical officer of ImmunityBio, Inc., a registration stage immuno-oncology and infectious disease company, since March 2019. Before that, Dr Lee served as senior vice president of clinical development of Nantkwest, Inc., an innovative clinical-stage immunotherapy company, from May 2016 to May 2020. Dr Lee served as executive director of the Chan Soon Shiong Institute of Molecular Medicine, a biomedical and translational research institute and as a full professor at the University of South Dakota, from May 2016 to September 2018 and September 2010 to May 2016, respectively. Dr Lee served as director of the cancer center of Stanford Health, a leading academic health system from July 2012 to May 2016. Dr Lee served as a member of the board of directors of Windber Hospital from June 2018 to May 2020. Dr Lee received a BS in biology from Stanford University, an MD from the University of Minnesota, Twin Cities, and special training in otolaryngology-head and neck surgery from the University of Iowa.
Chris Lowe, MBA
Christopher Lowe, MBA is a member of Vincerx’s board of directors. Mr Lowe has served as chief financial officer of Cortexyme, Inc., a clinical-stage biopharmaceutical company, since January 2019. Prior to that, Mr Lowe served as a partner of FLG Partners, a professional services company, from January 2015 to April 2020. Mr Lowe also served as the Managing Partner of the Innventus Fund at Innventure, a venture capital firm, from January 2017 to March 2020 and as a member of the board of directors of Innventure from August 2016 to January 2020. From January 2015 to December 2018, Mr Lowe served as chief financial officer of Sentreheart, Inc., a biotechnology company. Mr Lowe served as the interim chief executive officer and chief financial officer of Hansen Medical, a medical robotics company listed on Nasdaq prior to its acquisition by Auris Surgical Robotics in 2016, from February 2014 to July 2016. Mr Lowe served as a director for Inspyr Therapeutics, Inc., an integrated biopharmaceutical company, from September 2016 to December 2018. He also served as a director of EpiBiome, Inc., a microbiome engineering company, from May 2016 to June 2018, and as a director and chairman of the audit committee for Asante Solutions, Inc., a medical device company, from December 2014 to October 2015. Mr Lowe holds a BS in business administration from California Polytechnic State University and an MBA from St. Mary’s University, Texas.
Financial Expert
Mark McCamish, MD, PhD
Mark McCamish, MD, PhD is a member of Vincerx’s board of directors. From May 2016 to July 2020, Dr McCamish has served as president, chief executive officer and member of the board of directors of Forty Seven, Inc., a clinical-stage biopharmaceutical company, which was acquired by Gilead Sciences, Inc. in July 2020. From July 2009 to September 2016, Dr McCamish served as global head of biopharmaceutical development at Sandoz Inc., a pharmaceutical company. Since December 2019, Dr McCamish has served as a member of the compensation committee and the board of directors of Avadel Pharmaceuticals PLC , a pharmaceutical development company. Dr McCamish received a BA in Physical Education and an MA in Ergonomics from the University of California at Santa Barbara, a PhD in Nutritional Sciences from the Pennsylvania State University and an MD from the University of California at Los Angeles.
Andrew McDonald, PhD
Andrew McDonald, PhD is a member of Vincerx’s board of directors. Dr McDonald has served as chief executive officer and as a member of the board of directors of LSAC since June 2019. Dr McDonald has served as chief executive officer of Attune Pharmaceuticals, a clinical-stage biotechnology company, since March 2015 and is a founding partner of LifeSci Advisors, LLC, a life sciences investor relations consultancy company, and LifeSci Capital, LLC, an emerging life sciences investment bank. Before founding LifeSci Advisors, LLC, and LifeSci Capital, LLC, in March 2010, Dr McDonald served as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund, from 2006 to 2008. From 2004 to 2006, Dr McDonald served as head of healthcare research and a biotechnology analyst at ThinkEquity Partners, a boutique investment bank. Before entering the financial services industry, Dr McDonald was a medicinal chemist at Cytokinetics, Inc., a biopharmaceutical company, from 2001 to 2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Dr McDonald began his pharmaceutical career as a medicinal chemist at Pfizer. Dr McDonald received a PhD in organic chemistry from University of California, Irvine and completed his BS in chemistry at University of California, Berkeley. Dr McDonald holds Series 7, 24, 63, 79, 86, and 87 licenses.
Francisco Salva
Francisco D. Salva is a member of Vincerx’s board of directors. Mr Salva has served as an operating partner of Accelerator Life Science Partners, a venture capital firm, since January 2018, and served as president and chief executive officer of Complexa Inc., a clinical-stage biopharmaceutical company, from May 2018 to August 2020. Mr Salva co-founded Acerta Pharma and served as its vice president of operations from February 2013 to November 2016. Before that, Mr Salva served as senior director of corporate finance at Pharmacyclics. Mr Salva received an AB in business economics and an AB in philosophy from Brown University and a MSc in economics and philosophy form the London School of Economics.

Investor Tools

Print Page
Email Alerts
RSS Feeds
Contact IR
Menu